OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that the company's T-SPOT®.TB test has completed the re-registration process with the China Food and Drug Administration (CFDA). The registration became effective December 11, 2014 and lasts for five years.
"We are pleased to have completed re-registration of our T-SPOT.TB test and look forward to continuing to work with our partner Fosun Pharmaceuticals to further grow the adoption of our technology in China," said Dr. Peter Wrighton-Smith. "As the re-registration occurred in line with our expected timing, we do not expect any disruption to our business in China."
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's initial product is the T-SPOT.TB test, which is used to test for latent tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.TB test utilizes the proprietary T-SPOT technology platform that measures the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. The Company has an additional six products based on either T-SPOT or innate immunity technology platforms in various stages of development. The two most advanced products are focused on the transplantation market and test for CMV infection and organ rejection. The Company is headquartered near Oxford, UK and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer,
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0500
Source: Oxford Immunotec